Zacks small cap research.

Genasys (. GNSS Quick Quote. GNSS - Free Report) has an Earnings ESP of +21.74% and a Zacks Rank #2. GNSS is scheduled to release fourth-quarter fiscal 2023 …

Zacks small cap research. Things To Know About Zacks small cap research.

SCR Premium. Receive Initiation Reports PROMPTLY as they are sent out to the marketplace. Access the FULL REPORT CATALOG on any company we cover. Receive the DAILY ALERT EMAIL, containing all of the day's updates, around 5 p.m. EST. Access to REAL-TIME EMAIL ALERTS for any companies covered by Zacks SCR analysts.. …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, ...For the quarter ending March 31, 2023, electroCore Inc. (NASDAQ:ECOR) posted revenues of approximately $2.8 million vs. $1.9 million in the prior year quarter. This represents growth of nearly 50%, driven by increases in the VA/DOD segment and commercial revenues augmented by electroCore’s cash pay initiatives.Apr 1, 2021 · By John Vandermosten, CFA NASDAQ:RVPH RP5063: Retroactive Comparison Against 32 Antipsychotics An estimated 0.25% to 1% of the global population suffers from schizophrenia. To address this estimated 20 million individuals with the chronic disorder there are numerous antipsychotics approved for use. However, a high discontinuation rate due to suboptimal efficacy and serious side effects reveals an

By Brad Sorensen, CFA OTC:CLMEF READ THE FULL CLMEF RESEARCH REPORT We are reiterating are positive view on Calima Energy (OTC:CLMEF) and urging investors to take a look at a company with an in-demand asset that is well run, cares about shareholders, and is trading well below our conservative valuation of $0.55/share. …

Put on Your Rally Cap, as We Turn the Last Two Inside-Out Do you get the sense that folks were more bullish after last Wednesday's rally than they were after Monday's rally? That's the sense I get. I suppose that is because last week's rug ...

Research and development expenses in the 3rd quarter of 2023 were $469,000 which was similar to R&D expenses in the 3rd quarter of 2022 of $468,000. R&D expenses include the use of third-party contractors for further R&D activities, the performance of usability studies for the PressureSafe device, and non-cash expenses relating to stock-based ...By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT First Quarter 2023 Results MiMedx Group, Inc. (NASDAQ:MDXG) reported first quarter 2023 revenues of $71.7 million, representing a 22% year over year growth rate, surpassing our $64.2 million estimate. Loss from operations was ($3.4) million, …By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT First Quarter 2023 Results MiMedx Group, Inc. (NASDAQ:MDXG) reported first quarter 2023 revenues of $71.7 million, representing a 22% year over year growth rate, surpassing our $64.2 million estimate. Loss from operations was ($3.4) million, …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Do you know how to make a bottle cap necklace? Find out how to make a bottle cap necklace in this article from HowStuffWorks. Advertisement A bottle cap necklace makes a great party gift and is perfect for an arts and craft project. There a...

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research. Read full article. Gain Therapeutics, Inc. December 4, 2023 at …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

3 Top-Ranked Beaten-Down Tech Stocks to Buy... AWS 10/6: Jobs Numbers Double to 336K on... PFP 10/6: All Eyes on This Morning's Jobs... Top Stock Reports for Alphabet, Sanofi &... A complete...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.Nov 16, 2023 · Net R&D expenses for the third quarter of 2023 were $3.3 million, compared to $3.8 million during the third quarter of 2022. The decrease was primarily due to decreased costs related to the Phase 3 clinical trial and decreased payroll expense, travel, materials, depreciation, and other activities. G&A expenses for the third quarter of 2023 were ...

On February 6, 2023, Arrowhead announced financial results for the first quarter of fiscal year 2023 that ended December 31, 2022. The company reported revenue of approximately $62.5 million for the first quarter of fiscal year 2023 compared to approximately $27.4 million for the first quarter of fiscal year 2022.© Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window)INXDF: INXDF is Changing the Digital Financial World. INX Digital (OTCQB:INXDF) is a company that provides a regulated platform where verified customers can trade cryptocurrencies and security tokens on a secure and around the clock basis. The security token market appears poised to explode and INX is the only company to this …Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE. _____ 1. The 0.68 Hazard Ratio was better than and below the pre-specified cutoff of 0.721. 2. Compiled by Zacks’ analysts from company press …Novonix Cathode Materials is also expected to play a key role in the growing demand for batteries. Last month NVX launched a new pilot production facility for cathode materials in a new 35,000-square-foot facility. The facility enables Novonix to demonstrate the feasibility of large-scale production.

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Fourth Quarter and Fiscal Year 2021 Financial and Operational Results On March 15, 2022, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) announced fourth quarter and fiscal year 2021 financial and operational results and filed …Aug 19, 2022 · Reviva’s Phase III trial designated RECOVER is now underway, a four-week efficacy study followed by a one-year safety extension. The trial will target enrollment of 400 subjects, which as of July 2022 was 20% achieved and continuing to progress slightly ahead of schedule. Based on the construction of the study, which could be extended due to ...

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update IGALMI™ Approved by the FDA On April 6, 2022, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced that the U.S ...OTC:NEXCF. READ THE FULL NEXCF RESEARCH REPORT. Nextech AR’s (OTC:NEXCF) Q3 report showed a rapid uptake of its AR 3D model subscription business which grew 192% sequentially. It plans to deliver $700,000 worth of models to Amazon (we believe) alone in Q4 and the business continues to thrive. Just as …Aug 19, 2022 · Reviva’s Phase III trial designated RECOVER is now underway, a four-week efficacy study followed by a one-year safety extension. The trial will target enrollment of 400 subjects, which as of July 2022 was 20% achieved and continuing to progress slightly ahead of schedule. Based on the construction of the study, which could be extended due to ... TOL Quick Quote. TOL. 81.27. +9.45%. Compare funds in the Small-Cap-ETFs. Compare similar funds using our ETF Categories. Zacks Investment Research. Our Research, Your Success.Zacks now provides investment data, market data systems, proprietary quantitative models, analyst written research, investor relations,. SEC compliance and XBRL ...Alpha-1062 Extended-Release Bioequivalence Study Topline Results. Results from the second bioequivalence study were shared with investors a few weeks ago on August 22, 2022. The data demonstrated pharmacokinetic equivalence between 5 mg of Alpha-1062 delayed release tablets and 8 mg galantamine hydrobromide extended …On February 6, 2023, Arrowhead announced financial results for the first quarter of fiscal year 2023 that ended December 31, 2022. The company reported revenue of approximately $62.5 million for the first quarter of fiscal year 2023 compared to approximately $27.4 million for the first quarter of fiscal year 2022.Nov 22, 2023 · Research and development expenses in the 3rd quarter of 2023 were $469,000 which was similar to R&D expenses in the 3rd quarter of 2022 of $468,000. R&D expenses include the use of third-party contractors for further R&D activities, the performance of usability studies for the PressureSafe device, and non-cash expenses relating to stock-based ... Nov 14, 2023 · A conference call was also held to discuss results with investors. For the third quarter of 2023 ending September 30, 2023 and versus the prior year’s third quarter, no revenues were recognized. Net loss for the third quarter totaled ($73.5) million or ($4.89) per share. Operational expenses rose 67% over 3Q:23 levels as increases related to ...

That is the S&P 500 performance. So over the last 35 years, the S&P has averaged 10.5%, and the stocks that Zacks ranks as #1 Strong Buy are up 24.3%. So they BEAT THE S&P 500 BY 13.8% on average each year. On top of that, stocks that are ranked as #5 Strong Sell are only up 2.2%, so they’re underperforming the market.

For the quarter ending September 30, 2022 and versus the same comparable prior year period: Research & development expenses totaled $702,000, falling 76% from $3.0 million on account of a reversal of amounts paid to a service provider and lower spending on LP-100. These movements were partially offset by recognition of expenses …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …RVLP: Bright-Eyed and Bushy-Tailed. 04/10/2023. By John Vandermosten, CFA. NASDAQ:RVLP. The Journal of Plastic, Reconstructive and Aesthetic Surgery published an article entitled The Effect of Topical Oxymetazoline on Eyelid Position, Eye Redness, and Patient-Reported Eye Appearance: A Randomized Controlled Trial.Similar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers.Mar 3, 2023 · By Brad Sorensen, CFA OTC:FRXIF READ THE FULL FRXIF RESEARCH REPORT Demand continues to increase for a flame retardant that doesn’t have toxic chemicals and the Nofia product from FRX Innovations (OTC:FRXIF), an eco-friendly flame retardant solution, is the perfect solution. Studies previously cited by the FRX note that over 60% of fire-retardant plastic formulations are based on Nov 27, 2023 · On November 19, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) were presented at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) ( Lauko et al., 2023 ). The Phase 2 clinical trial enrolled 62 GBM patients (36 newly diagnosed and 26 ... Zacks Small-Cap Research Tom Kerr 312-265-9147 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 November 14, 2022 UPDATE: Siyata reported 2022 3rd quarter financial results which showed high revenue growth rates compared to the prior year period. Utilizing a DCF valuation process containingSUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Knowing which ridge cap you can use for an architectural roof, and which you should not is vitally important to the longevity of the roof. Expert Advice On Improving Your Home Videos Latest View All Guides Latest View All Radio Show Latest ...Zacks Investment Research has three different main subscription plans: Zacks Premium, Zacks Investor Collection, and Zacks Ultimate. Zacks Premium costs …By David Bautz, PhD. NASDAQ:MDNA. READ THE FULL MDNA RESEARCH REPORT. Business Update. Update on ABILITY Trial. Medicenna Therapeutics Corp. (NASDAQ:MDNA) is currently conducting the Phase 1/2 ABILITY Study (A Beta-only IL-2 ImmunoTherapY Study) of MDNA11 in patients with advanced solid …

© Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window)A new baseball hat tends to be stiff and uncomfortable, and many people prefer the look of an worn-in hat. Fortunately, fading and distressing a baseball cap is quite easy to do. To prepare for the fading process, wet the bill of the hat.Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Reviva RECOVER Topline Results Data Presentation, October 30, 2023.On February 6, 2023, Arrowhead announced financial results for the first quarter of fiscal year 2023 that ended December 31, 2022. The company reported revenue of approximately $62.5 million for the first quarter of fiscal year 2023 compared to approximately $27.4 million for the first quarter of fiscal year 2022.Instagram:https://instagram. can i buy shiba inu on robinhoodtraders edge reviewtop ten long term stocksciam market By Brad Sorensen, CFA OTC:FRXIF READ THE FULL FRXIF RESEARCH REPORT Demand continues to increase for a flame retardant that doesn’t have toxic chemicals and the Nofia product from FRX Innovations (OTC:FRXIF), an eco-friendly flame retardant solution, is the perfect solution. Studies previously cited by the FRX note that over 60% of fire-retardant plastic formulations are based on how much is aaa renters insurance0go By John Vandermosten, CFA. NYSE:NHWK. READ THE FULL NHWK RESEARCH REPORT. The recently renamed NightHawk Biosciences, Inc. (NYSE:NHWK) reported first quarter 2022 results on May 16, 2022 and filed its Form 10-Q with the SEC. It has been a whirlwind year for the company as it made an acquisition, expanded its … apple watch vo2 SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Financial Results. In its latest fiscal quarter ending December 31 st, IBS generated total revenues of $626,000 compared to $178,000 in the prior year period. 2Q:23 revenues included a component from both Intelligent Fingerprinting (IFP) and government support revenue while 2Q:22 revenues only included the government support component ...